Article

Novel compound shows promise for dry eye in proof-of-concept study

Author(s):

Julianne Mobilian
Conferences|ASCRS

Topical drug for the treatment of dry eye disease sees potential 

Eric D. Donnenfeld, MD, FAAO, shares results from an ex-U.S. proof-of-concept study investigating a novel, small peptide anti-integrin topical therapy (ALG-1007, Allegro Ophthalmics) for the treatment of dry eye disease. He presented his research at the 2019 annual ASCRS meeting in San Diego.

RELATED: Sustained-release implant promising for long-term IOP reduction

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
(Image credit: Ophthalmology Times) ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
Related Content
Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery
May 18th 2025

Q&A: Eva Kim, MD, on the value of EVO ICL for patients considering surgery

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

EyeCool Therapeutics announces results from pilot study of novel chronic ocular surface pain treatment
May 14th 2025

EyeCool Therapeutics announces results from pilot study of novel chronic ocular surface pain treatment

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)
September 13th 2023

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops
May 10th 2025

Monique Barbour, MD, highlights benefits of dropless protocol over traditional drops

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap
May 7th 2025

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap

© 2025 MJH Life Sciences

All rights reserved.